Your browser doesn't support javascript.
loading
Novel insight into atogepant mechanisms of action in migraine prevention.
Melo-Carrillo, Agustin; Strassman, Andrew M; Broide, Ron; Adams, Aubrey; Dabruzzo, Brett; Brin, Mitchell; Burstein, Rami.
Afiliación
  • Melo-Carrillo A; Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center. Boston, MA 02115, USA.
  • Strassman AM; Harvard Medical School, Harvard University, Boston, MA 02115, USA.
  • Broide R; Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center. Boston, MA 02115, USA.
  • Adams A; Harvard Medical School, Harvard University, Boston, MA 02115, USA.
  • Dabruzzo B; Allergan, an Abbvie Company, Irvine, CA 92612, USA.
  • Brin M; Allergan, an Abbvie Company, Irvine, CA 92612, USA.
  • Burstein R; Allergan, an Abbvie Company, Irvine, CA 92612, USA.
Brain ; 147(8): 2884-2896, 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-38411458
ABSTRACT
Recently, we showed that while atogepant-a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist-does not fully prevent activation of meningeal nociceptors, it significantly reduces a cortical spreading depression (CSD)-induced early response probability in C fibres and late response probability in Aδ fibres. The current study investigates atogepant effect on CSD-induced activation and sensitization of high threshold (HT) and wide dynamic range (WDR) central dura-sensitive trigeminovascular neurons. In anaesthetized male rats, single-unit recordings were used to assess effects of atogepant (5 mg/kg) versus vehicle on CSD-induced activation and sensitization of HT and WDR trigeminovascular neurons. Single cell analysis of atogepant pretreatment effects on CSD-induced activation and sensitization of central trigeminovascular neurons in the spinal trigeminal nucleus revealed the ability of this small molecule CGRP receptor antagonist to prevent activation and sensitization of nearly all HT neurons (8/10 versus 1/10 activated neurons in the control versus treated groups, P = 0.005). In contrast, atogepant pretreatment effects on CSD-induced activation and sensitization of WDR neurons revealed an overall inability to prevent their activation (7/10 versus 5/10 activated neurons in the control versus treated groups, P = 0.64). Unexpectedly however, in spite of atogepant's inability to prevent activation of WDR neurons, it prevented their sensitization (as reflected their responses to mechanical stimulation of the facial receptive field before and after the CSD). Atogepant' ability to prevent activation and sensitization of HT neurons is attributed to its preferential inhibitory effects on thinly myelinated Aδ fibres. Atogepant's inability to prevent activation of WDR neurons is attributed to its lesser inhibitory effects on the unmyelinated C fibres. Molecular and physiological processes that govern neuronal activation versus sensitization can explain how reduction in CGRP-mediated slow but not glutamate-mediated fast synaptic transmission between central branches of meningeal nociceptors and nociceptive neurons in the spinal trigeminal nucleus can prevent their sensitization but not activation.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Depresión de Propagación Cortical / Ratas Sprague-Dawley / Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina / Trastornos Migrañosos Límite: Animals Idioma: En Revista: Brain Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Depresión de Propagación Cortical / Ratas Sprague-Dawley / Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina / Trastornos Migrañosos Límite: Animals Idioma: En Revista: Brain Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos